These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 14977297)

  • 1. Combating antiretroviral resistance.
    Jordan W
    J Natl Med Assoc; 2004 Feb; 96(2 Suppl):31S-32S. PubMed ID: 14977297
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand.
    Apisarnthanarak A; Mundy LM
    Clin Infect Dis; 2008 May; 46(10):1630-1. PubMed ID: 18419506
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects.
    Vicenti I; Razzolini F; Saladini F; Romano L; Zazzi M
    Clin Infect Dis; 2007 Jun; 44(12):1657-61. PubMed ID: 17516412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV resistance testing. A clinical tool.
    Paul SM; Jorden VS
    N J Med; 2003 Sep; 100(9 Suppl):44-9; quiz 75-6. PubMed ID: 14556603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.
    Palombi L; Galluzzo CM; Pirillo MF; Liotta G; Andreotti M; Jere H; Sagno JB; Luhanga R; Mancinelli S; Ceffa S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2014 Mar; 69(3):749-52. PubMed ID: 24135952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of an empirical antiretroviral treatment depends on the primary resistance rate of the human immunodeficiency virus].
    Fernández Gutiérrez Del Álamo C; López Tinoco E; Fernández Rodríguez A; Soto Cárdenas MJ; Lozano Domínguez C; Bernal Martínez S; Guerrero Sánchez F; Girón-González JA
    Enferm Infecc Microbiol Clin; 2012 Nov; 30(9):542-8. PubMed ID: 22365617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global status of resistance to antiretroviral drugs.
    Vella S; Palmisano L
    Clin Infect Dis; 2005 Aug; 41 Suppl 4():S239-46. PubMed ID: 16032559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV drug resistance testing.
    Cane P
    Methods Mol Biol; 2011; 665():123-32. PubMed ID: 21116799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.
    Ruane PJ; Daar ES
    AIDS Read; 2004 Sep; 14(9):487-98. PubMed ID: 15457602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug targets for HIV.
    Bean P
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S96-100. PubMed ID: 16265623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antiretroviral drug resistance.
    Wainberg MA; Zaharatos GJ; Brenner BG
    N Engl J Med; 2011 Aug; 365(7):637-46. PubMed ID: 21848464
    [No Abstract]   [Full Text] [Related]  

  • 12. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate levels of transmitted antiretroviral drug resistance in Midwestern Brazil.
    Pfrimer IA; Bizinoto MC; Brandão NA; Camargo M; Sucupira MC; Janini LM; Diaz RS
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):205-6. PubMed ID: 22978276
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV in 2010: potent antiretroviral drugs treat and sensitive assays monitor the infection; but there remain outstanding issues.
    Antonelli G
    Clin Microbiol Infect; 2010 Oct; 16(10):1509-10. PubMed ID: 20854461
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV clinical trial design for antiretroviral development: moving forward.
    Chan-Tack KM; Struble KA; Morgensztejn N; Murray JS; Gulick R; Cheng B; Weller I; Miller V
    AIDS; 2008 Nov; 22(18):2419-27. PubMed ID: 19005265
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.
    Monge S; Guillot V; Alvarez M; Peña A; Viciana P; García-Bujalance S; Pérez Elias MJ; Iribarren JA; Gutiérrez F; Itziar Casado M; Garcia F;
    Clin Microbiol Infect; 2012 Nov; 18(11):E485-90. PubMed ID: 23016666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
    Lamorde M; Schapiro JM; Burger D; Back DJ
    AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rates of transmitted drug resistance among newly-diagnosed antiretroviral naïve HIV patients in Northern Greece, data from 2009-2011.
    Skoura L; Metallidis S; Pilalas D; Kourelis A; Margariti A; Papadimitriou E; Antoniadou ZA; Chrysanthidis T; Tsachouridou O; Kollaras P; Nikolaidis P; Malisiovas N
    Clin Microbiol Infect; 2013 Mar; 19(3):E169-72. PubMed ID: 23331664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
    Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
    J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral drug resistance and fitness.
    Quiñones-Mateu ME; Moore-Dudley DM; Jegede O; Weber J; J Arts E
    Adv Pharmacol; 2008; 56():257-96. PubMed ID: 18086415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.